AICAR is a small molecule, not a peptide: 5-aminoimidazole-4-carboxamide ribonucleoside, formula C9H14N4O5, molecular weight 258.23 g/mol, CAS 2627-69-2. Inside a cell it is phosphorylated to the corresponding monophosphate, known as ZMP, which mimics AMP and activates AMP-activated protein kinase (AMPK) without changing the cell's ATP, ADP or AMP content. Under the name acadesine it reached a large randomized cardiac surgery trial that was stopped for futility in 2012; it is not approved as a drug, and it is named on the World Anti-Doping Agency's 2026 Prohibited List.
This profile covers the chemistry and nomenclature, the AMPK mechanism as Corton and colleagues described it in 1995, the caveat that a 2021 systematic review placed on interpreting experiments with it, the models and trials on record, and the handling points for a nucleoside reagent.
Identity at a glance
The values below come from the PubChem record for AICAR (CID 17513).
| Property | Value |
|---|---|
| Name | AICAR; AICA riboside; AICAr; acadesine (INN) |
| Systematic name | 5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide |
| Class | Nucleoside analog (small molecule), not a peptide |
| Molecular formula | C9H14N4O5 |
| Molecular weight | 258.23 g/mol |
| CAS number | 2627-69-2 |
| PubChem CID | 17513 |
| XLogP | −2.2 (strongly hydrophilic) |
| Active intracellular form | ZMP, the 5'-monophosphate |
| Molecular target | AMP-activated protein kinase, via the AMP-binding sites of the γ subunit |
Structurally this is a ribose sugar joined through an N-glycosidic bond to an aminoimidazole carboxamide base. Swap that base for adenine and you have adenosine; the aminoimidazole carboxamide ring is a biosynthetic precursor of the purine ring, which is the key to both its natural role and its use as a tool.
Nomenclature: riboside, ribotide and ZMP
The abbreviation AICAR is used for two different molecules in two different literatures, and confusing them makes papers hard to read.
| Term | Molecule | Where it appears |
|---|---|---|
| AICAR, AICAr, AICA riboside | The nucleoside, C9H14N4O5, 258.23 g/mol | Cell biology and signaling papers; this is the reagent sold as AICAR |
| AICAR (ribotide), ZMP | The 5'-monophosphate formed inside cells | Purine metabolism papers; an intermediate of de novo purine synthesis |
| Acadesine | International nonproprietary name for the nucleoside | Trial registries, regulatory documents |
The nucleoside is what a laboratory weighs out. Once it crosses the membrane it is phosphorylated to the monophosphate, the step generally attributed to adenosine kinase. That monophosphate, ZMP, is also a normal metabolite: in de novo purine biosynthesis it is the substrate of the bifunctional enzyme ATIC, which formylates it and closes the ring on the way to inosine monophosphate. Block or slow that step, or push flux into the pathway, and ZMP accumulates on its own, which is how the same intermediate appears in the mechanism of the antifolate methotrexate and in the published account of the mitochondrial-derived peptide MOTS-c.
How it activates AMPK
AMPK is a heterotrimeric enzyme, an α catalytic subunit with β and γ regulatory subunits. Its activity is governed by the γ subunit's nucleotide-binding sites: AMP binding activates the kinase allosterically and also makes the activating phosphorylation on the α subunit harder to remove, so the two effects compound.
Corton, Gillespie, Hawley and Hardie set out the case for AICAR as a tool in the European Journal of Biochemistry in 1995, in a paper whose title is a question: whether this was a specific method for activating AMPK in intact cells. Working with isolated rat hepatocytes, they reported that:
- Incubation with AICAR led to accumulation of ZMP inside the cell.
- ZMP mimicked both activating effects of AMP on AMPK, the direct allosteric activation and the promotion of phosphorylation by the upstream kinase then called AMPK kinase.
- Unlike earlier ways of activating AMPK in intact cells, such as fructose loading or heat shock, AICAR did not perturb cellular ATP, ADP or AMP content. This is the property that makes it a tool rather than a blunt metabolic stress.
- Downstream, they observed phosphorylation and inactivation of HMG-CoA reductase, a known AMPK target, and near-complete cessation of fatty acid and sterol synthesis.
- In isolated adipocytes, AICAR antagonized isoprenaline-stimulated lipolysis, which the authors read as evidence that AMPK's inhibition of hormone-sensitive lipase activation by cyclic-AMP-dependent protein kinase, previously shown in cell-free assays, also operates in intact cells.
That paper is the origin of AICAR's standing as the default pharmacological AMPK activator, a position it held through most of the field's early literature.
The caveat: AMPK-independent effects
A systematic review by Višnjić and colleagues in Cells in 2021 is the necessary counterweight. Their survey of the literature found a growing number of AICAR effects that had been attributed to AMPK activation but are in fact AMPK-independent, across metabolism, hypoxia signaling, exercise biology, nucleotide synthesis and cancer models. Their conclusion is a methodological one: experiments that rest on AICAR alone cannot establish that an observation is AMPK-mediated, and interpretations built on AICAR-only designs should be read with caution.
The reasons are visible in the chemistry above. ZMP is not only an AMP mimic; it is a real purine-pathway intermediate with its own enzyme interactions, and loading a cell with it perturbs purine metabolism as well as AMPK signaling. Modern designs therefore pair AICAR with genetic approaches, such as AMPK subunit knockout or knockdown, or with structurally unrelated activators.
Research and trial record
In the laboratory, AICAR has been used across isolated hepatocytes, adipocytes, skeletal muscle preparations, and a wide range of cultured cell lines, as well as rodent models in metabolic and cardiac ischemia research. It is one of the most heavily cited pharmacological tools in the AMPK field, which is precisely why the 2021 review's caution matters.
In human research it was developed as acadesine, described as a first-in-class adenosine-regulating agent, for ischemia-reperfusion injury in cardiac surgery. The RED-CABG trial, reported in JAMA in 2012 by Newman and colleagues, was a randomized, double-blind, placebo-controlled study at 300 sites in seven countries in patients undergoing non-emergency on-pump coronary artery bypass grafting. The primary endpoint was a composite of all-cause mortality, non-fatal stroke and the need for mechanical support for severe left ventricular dysfunction through postoperative day 28. A prespecified futility analysis indicated a very low likelihood of a statistically significant efficacious outcome, and the trial was stopped after 3,080 of the projected 7,500 participants had been randomized. The composite endpoint occurred at essentially the same rate in both groups. That trial, registered as NCT00872001, is the largest human dataset on the compound.
Regulatory and anti-doping status
Acadesine is not an approved drug in the United States, and no approval elsewhere appears in the sources cited here. Its regulatory history is that of a compound that advanced to a large randomized trial and missed its primary endpoint.
In sport, the 2026 World Anti-Doping Agency Prohibited List names AICAR at S4.4.1, under activators of AMP-activated protein kinase, within S4, hormone and metabolic modulators. The same entry names MOTS-c and BAM15. S4 substances are prohibited at all times, in and out of competition.
Material sold by Anhydrolabs is supplied for in-vitro laboratory research only, and is not for human or veterinary diagnosis, treatment, or consumption.
Laboratory handling and storage
AICAR is supplied as a lyophilized powder in vacuum-sealed vials, on the AICAR catalog page and in 10-vial kits. As a nucleoside it behaves differently from the peptides in this catalog, and differently again from the quaternary salt 5-Amino-1MQ.
Solubility. With an XLogP of −2.2 and three hydroxyl groups on the ribose plus a carboxamide, AICAR is strongly hydrophilic and water is the usual solvent for stock solutions. Warm, well-mixed water dissolves it more readily than cold; measure solubility at the working concentration rather than assuming a number.
Acid and the glycosidic bond. The N-glycosidic bond that joins the base to the ribose is the hydrolytically weak point of any nucleoside, and acidic conditions promote depurination-type cleavage. Keep solutions near neutral pH, and do not store stocks in acidified water.
Light, moisture and temperature. Store the sealed solid frozen, dry and dark, with desiccant, and let vials equilibrate to room temperature before opening so moisture does not condense onto the solid. Aqueous stocks should be aliquoted for single use and frozen; the general logic is the same as for peptides, set out in how to store peptides and on the storage and handling page.
Analytics. Identity is established by NMR and by LC-MS, where the expected monoisotopic mass corresponds to the C9H14N4O5 formula in the table. Purity is reported by HPLC-UV as the area of the principal peak, the aminoimidazole carboxamide ring providing a usable chromophore. Two impurity classes are worth reading a certificate for: the free base, meaning the aminoimidazole carboxamide without the sugar, which indicates glycosidic hydrolysis, and residual solvents from the final crystallization. The general approach to reading such a document is described in how HPLC measures purity.


